Total Voting Rights and Block Listing Return
01/07/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220701:nRSA9243Qa&default-theme=true
RNS Number : 9243Q Ergomed plc 01 July 2022
Total Voting Rights and Block Listing Return
Total Voting Rights
Guildford, UK - 1 July 2022: In accordance with the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules ("DTRs"), Ergomed plc
(the "Company") announces the following information.
The Company's issued share capital as at 30 June 2022 consisted of 49,880,029
shares of 1p each, none of which were held in treasury. Each ordinary share
in the capital of the Company carries one voting right.
The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company, under the DTRs.
Block Listing Six Monthly Return
Name of applicant: Ergomed plc
Name of scheme: Ergomed plc Long Term Incentive Plan
Period of return: From: 1 January 2022 To: 30 June 2022
Balance of unallotted securities under scheme(s) from previous return: 1,908,177
Plus: The amount by which the block scheme(s) has been increased since the 0
date of the last return (if any increase has been applied for):
Less: Number of securities issued/allotted under scheme(s) during period (see 586,400
LR3.5.7G):
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 1,321,777
Number and class of securities originally admitted and the date of admission 1,800,000 ordinary shares of 1p each - 2 July 2018
1,500,000 ordinary shares of 1p each - 31 December 2019
600,000 ordinary shares of 1p each - 7 July 2021
Total number of securities in issue at the end of the period 49,880,029 ordinary shares of 1p each
Name of contact: Fiona Mundy - Director of Group Reporting
Telephone number of contact: +44 (0) 7854825324
ENDS
Enquiries:
Ergomed plc
Tel: +44 (0) 1483 402 975
Dr Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital Markets & Strategy)
Numis
Tel:
+44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP
Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher Golden
Consilium Strategic Communications
Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal
ergomed@consilium-comms.com
Angela Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing services business includes an
industry-leading suite of specialist pharmacovigilance (PV) solutions,
integrated under the PrimeVigilance brand, a full range of high-quality
clinical research and trial management services under the Ergomed brand (CRO)
and mission-critical regulatory compliance and consulting services under the
ADAMAS brand. For further information, visit: http://ergomedplc.com
(http://ergomedplc.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END TVRBBLLXLQLFBBL